ModifiedUnitedHealthcarePolicy CS198KS.02

Chemotherapy Observation or Inpatient Hospitalization (for Kansas Only)

Defines when cancer chemotherapy or related treatments for adults (18+) in Kansas require facility observation or inpatient hospitalization and who is affected (providers and members in the Kansas UnitedHealthcare Community Plan).

Policy Summary

PayerUnitedHealthcare

PolicyChemotherapy Observation or Inpatient Hospitalization (for Kansas Only)

Policy CodePolicy CS198KS.02

Change TypeRevised inpatient regimen requirementsremoved cancer-type lists

Effective Date06/01/2026

Next Review DateN/A

Key ActionObtain authorization using InterQual criteria (or UnitedHealthcare medical policy criteria if InterQual is unavailable) and follow written protocols for monitoring when admitting patients for multi-day chemotherapy regimens.

SourceLink

POLICY UPDATE CHANGES

Revised drug regimen requirements for an inpatient stay; removed list of applicable cancer type(s) for the listed regimens.

Updated Clinical Evidence and References sections to reflect the most current information.

Archived previous policy version CS198KS.01.

state-specificapplies to

>=18age restriction — policy does not apply to individuals under

multipleexamples of regimens requiring inpatient stay

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria — Observation vs Inpatient

Regimens requiring inpatient hospitalization

Inpatient hospitalization is medically necessary when ALL of the following apply for listed regimens or conditions:

Inpatient required for listed regimens: Regimens that require inpatient monitoring or complex administration over multiple days (examples provided): EPOCH / DA-EPOCH / R-EPOCH — continuous etoposide and doxorubicin infusions days 1–4 with cyclophosphamide day 5 (coordination of multiple infusions over ~96 hours); ESHAP / R-ESHAP — continuous infusions days 1–4 including high‑dose cytarabine and cisplatin (monitor for CNS toxicity with cytarabine); Interleukin‑2 infusion (600,000 IU/kg IV every 8 hours up to 14 doses over 5 days) requiring continuous cardiac and metabolic monitoring and proximity to intensive care; High‑dose ifosfamide (>1 g/m2/day) requiring close electrolyte and urine pH monitoring and replacement/alkalinization; High‑dose methotrexate (>500 mg/m2) with leucovorin rescue and serial serum methotrexate level monitoring; Hyper‑CVAD cycles that include multi‑day infusions, bladder irrigation, and close methotrexate/cytarabine monitoring.n/a

Examples are illustrative; see policy text for regimen‑specific drug dosing and monitoring parameters.

Conditions warranting observation

Observation stay may be appropriate for certain chemotherapy complications or when close short-term monitoring is needed; examples include:

Conditions/complications that may require observation: Clinical conditions or complications of cancer chemotherapy that may require an observation stay; policy notes these are examples and other situations will be reviewed case‑by‑case using InterQual LOC criteria.n/a

Refer to InterQual LOC for medical necessity determinations when not explicitly listed.

Explicit inpatient-only conditions

Conditions that explicitly require inpatient hospital stay:

Explicit inpatient-only conditions: Acute leukemia; intra-arterial infusion of chemotherapy (including transcatheter arterial chemoembolization / intra-arterial chemotherapy); prophylaxis of tumor lysis syndrome in cases of high‑grade lymphoma with large masses.n/a

These conditions are listed in the policy as requiring inpatient hospital stay.

Coverage Rationale (summary of revisions)

Summary of high-level changes to coverage rationale

policy-level changes: Drug regimen requirements for an inpatient stay were revised and the prior list of applicable cancer types for listed regimens was removed.

Supporting information, clinical evidence, and references were updated; previous policy version CS198KS.01 was archived effective 06/01/2026.

This policy applies to adults only. It does not apply to individuals under 18 years of age.

Information about U.S. Food and Drug Administration (FDA) approval is provided for reference only. FDA approval alone is not a basis for coverage. Coverage decisions are based on the member's benefit plan and the policy criteria rather than FDA marketing status.

Requests for observation or inpatient hospital treatment for conditions not explicitly listed in this policy will be evaluated individually. Such requests will be reviewed on a case-by-case basis using established level-of-care criteria (for example, InterQual® LOC) and must meet medical necessity based on the clinical circumstances.

Coverage determinations under this policy must be consistent with the member's federal, state, or contractual benefit plan. In the event of a conflict between this policy and a member's plan terms, the federal, state, or contractual requirements govern. Services outside those plan terms may be noncovered.

Regimens and Situations Requiring Inpatient Level Care

Regimen	Key details	Coverage stance
EPOCH / DA-EPOCH / R-EPOCH	Etoposide and doxorubicin continuous infusion days 1–4, vincristine days 1–4, cyclophosphamide day 5; coordination of multiple infusions over ~96 hours; outpatient delivery feasible in selected patients with close monitoring per published series	Covered

Regimen	Key details	Coverage stance
Ifosfamide (high-dose / 14-day ambulatory approaches)	Ifosfamide infusion >1 g/m2/day; close monitoring of serum electrolytes and urine pH, electrolyte replacement, urine alkalinization, mesna as indicated; literature describes outpatient 14-day continuous-infusion ambulatory approaches with elastomer pumps in selected patients	Covered

Regimen	Key details	Coverage stance
High‑dose methotrexate (>500 mg/m2) with leucovorin rescue	Methotrexate >500 mg/m2 requires leucovorin rescue (15 mg q6h ×8 starting 12 hours after infusion; escalate to 50 mg IV q6h per methotrexate level thresholds) and serial serum methotrexate level monitoring until <0.1 µmol/L	Covered

Regimen	Key details	Coverage stance
Interleukin‑2 infusion	Interleukin‑2 600,000 IU/kg IV every 8 hours up to 14 consecutive doses over 5 days; requires continuous cardiac monitoring, close electrolyte/renal/hepatic and urine output monitoring, and proximity to ICU/vasopressor support	Covered

Regimen	Key details	Coverage stance
Hyper‑CVAD	Cycles 1,3,5,7 include cyclophosphamide (multiple doses), continuous mesna, doxorubicin on day 4 and multi‑agent infusions; cycles 2,4,6,8 include methotrexate and high‑dose cytarabine components with close serum methotrexate monitoring and bladder irrigation as indicated; coordination of multiple infusions over ~96 hours supports inpatient care	Covered

Regimen	Key details	Coverage stance
Dose‑adjusted EPOCH, high‑dose cytarabine, and other intensive regimens	Updated literature reports outpatient delivery is feasible for some intensive regimens (e.g., DA‑EPOCH, high‑dose cytarabine) in selected patients/centers; policy revisions note supporting evidence and revised inpatient regimen requirements	mixed

Provider Requirements and Authorization Notes

Prior Authorization

Inpatient stay extension requires review

An inpatient stay is medically necessary for regimens that require inpatient monitoring or complex multi-day administration (examples include EPOCH/DA‑EPOCH/R‑EPOCH, ESHAP/R‑ESHAP, Interleukin‑2 infusion, high‑dose ifosfamide, high‑dose methotrexate with leucovorin rescue, Hyper‑CVAD, and other multi‑day or monitoring‑intensive protocols). Any requests for extension of the inpatient stay beyond the recommended days must be submitted for clinical review and may be denied if clinical justification is not provided.

Provider must submit clinical justification for inpatient stay extensions.
Extensions without adequate clinical documentation may be denied.

Documentation Required

Observation versus inpatient — case‑by‑case review

Case‑by‑case review determines whether an observation stay vs inpatient admission is appropriate. Clinical conditions or complications that may require observation include but are not limited to acute infusion reactions, transient electrolyte abnormalities, short‑term cardiac monitoring needs, or other complications expected to resolve within the observation period. Conditions that typically require inpatient admission include acute leukemia, intra‑arterial infusion of chemotherapy, and prophylaxis for tumor lysis syndrome in high‑grade lymphoma with large masses. When not explicitly listed, decisions will reference InterQual® LOC criteria for Hematology/Oncology (Complications, Disease Progression, and Treatments) and be reviewed on a case‑by‑case basis.

Definitions and Key Terms

TACE — procedure definition

TermTACE (Transcatheter Arterial Chemoembolization)

DefinitionA procedure in which the blood supply to a tumor is blocked after anticancer drugs are given in blood vessels near the tumor (National Cancer Institute, 2022).

Clinical contextTypically used to deliver locoregional chemotherapy while reducing tumor blood flow; may require interventional radiology resources and peri-procedural monitoring.

FDA approval (informational)

StatementFDA approval alone is not a basis for coverage.

Role of FDAFDA reviews data on a drug's safety and efficacy and grants approval when benefits outweigh risks for the intended population.

Background

Chemotherapy can be delivered in multiple settings including home, physician office, outpatient clinic, or inpatient hospital. The appropriate setting depends on the drug regimen, route and duration of administration, and the patient’s clinical status. Regimens that involve continuous or coordinated multi-day infusions, intensive physiologic monitoring, serial drug-level testing (for example, high-dose methotrexate), or procedures such as intra-arterial chemotherapy typically require inpatient-level monitoring. Patient comorbidities (for example, congestive heart failure or renal failure requiring high-volume fluids) or prior severe hypersensitivity reactions also influence the choice of setting.

Policy Revision History

06/01/2026policy_revisionLatest

Revised drug regimen requirements for inpatient stay; removed list of applicable cancer type(s) for the listed regimens; updated Clinical Evidence and References sections; archived previous policy version CS198KS.01.